about
attomarker

About Attomarker Ltd

Attomarker is a British company, founded in 2008 and spun out from Professor Andrew Shaw’s research group at the University of Exeter, specialising in nanophotonic biochemical testing. We have garnered numerous prestigious awards for innovation and have received grants from the UK Government in recognition of our significant contributions to diagnostics.  

Attomarker is dedicated to the personalised medicine market, providing gold-standard rapid diagnostics that facilitate better and timelier health decisions. We believe that new heath challenges require innovative solutions. By enabling rapid, personalised diagnosis, Attomarker aims to facilitate earlier treatment tailored to individual healthcare needs.  

High-quality diagnostics from Attomarker are designed to extend beyond laboratories, becoming accessible in clinics, pharmacies and even at home. This approach is reflected in the company’s name: ‘Atto’, which denotes a factor of 10-18, indicating our work in the realm of the very small. Attomarker develops complex multiplex tests based on new biomarkers or biomarker combinations, utilising our proprietary gold nanotechnology platform. Our mission is to provide the best possible diagnostic answers, closest to the point-of-care, regardless of how small the molecule or sample may be, thus revolutionising the science of diagnosis.  

Our Vision

At Attomarker, we believe that the evolving challenges to our health demand innovative solutions grounded in rigorous science. Our vision is to deliver rapid, personalised diagnostics that enable earlier treatments tailored to your unique healthcare needs. Committed to the principles of OneWorld Health, we strive to make high-quality diagnostics accessible to everyone — whether in clinics, pharmacies, or at home — bridging the gap between the laboratory and the global community.